Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma

Part of paid clinical trials in East Hanover, New Jersey.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT05714371
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This was a retrospective cohort study using the PharMetrics database. The analysis was conducted using the most recent 5 years of data from the database, January 1, 2015, to October 30, 2020. Included patients were followed for outcome evaluation from the index date (first prescription of treatment, immunotherapy \[IO\], or targeted therapy \[TT\] following diagnosis of non-metastatic malignant melanoma and evidence of first lymph node resection), until the first occurrence or end of continuous eligibility or end of the study period.

Key Dates

Start date
Oct 2, 2021
Status verified
Jan 2023
Primary completion
Jan 27, 2022
Completion
Jan 27, 2022

Study Design

Enrollment
618 participants (actual)

Arms

  • Arm: Immunotherapy (IO)
    Patients receiving IO
  • Arm: Targeted therapy (TT)
    Patients receiving TT

Primary Outcome Measure

Number of patients on first systemic adjuvant therapy with adverse avents (AEs) [ Time Frame: Up to approximately 5 years ]

Locations (1)

FacilityCityStateZIPSite coordinators
Novartis PharmaceuticalsEast HanoverNew Jersey07936-

Find similar trials in East Hanover, NJ

By condition
Melanoma
By specialty
OncologySkin cancerDermatology
By research site
Novartis Pharmaceuticals· East Hanover, NJ

Related Studies